Pomerantz probes Larimar after LRMR fell 33.66% and 12.57% on safety disclosures

The law firm is investigating whether Larimar Therapeutics and certain officers or directors misled investors as nomlabofusp study updates disclosed anaphylaxis cases in Friedreich’s Ataxia patients.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.